Dimethyl Fumarate - CAS 624-49-7
Catalog number: 624-49-7
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Dimethyl fumarate is an anti-inflammatory, a promising novel oral therapeutic option shown to reduce disease activity and progression in patients with relapsing-remitting multiple sclerosis.
Publictions citing BOC Sciences Products
  • >> More
1.Dimethyl fumarate attenuates intracerebroventricular streptozotocin-induced spatial memory impairment and hippocampal neurodegeneration in rats.
Majkutewicz I1, Kurowska E2, Podlacha M2, Myślińska D2, Grembecka B2, Ruciński J2, Plucińska K2, Jerzemowska G2, Wrona D2. Behav Brain Res. 2016 Apr 12;308:24-37. doi: 10.1016/j.bbr.2016.04.012. [Epub ahead of print]
Intracerebroventricular (ICV) injection of streptozotocin (STZ) is a widely-accepted animal model of sporadic Alzheimer's disease (sAD). The present study evaluated the ability of dimethyl fumarate (DMF), an agent with antioxidant and anti-inflammatory properties, to prevent spatial memory impairments and hippocampal neurodegeneration mediated by ICV injection of STZ in 4-month-old rats. Rodent chow containing DMF (0.4%) or standard rodent chow was made available on day 0. Rat body weight and food intake were measured daily for whole the experiment (21days). STZ or vehicle (SHAM) ICV injections were performed on days 2 and 4. Spatial reference and working memory were evaluated using the Morris water maze on days 14-21. Cells containing Fluoro-Jade B (neurodegeneration marker), IL-6, IL-10 were quantified in the hippocampus and choline acetyltransferase (ChAT) in the basal forebrain. The disruption of spatial memory and a high density of hippocampal CA1-3 cells labeled with Fluoro-Jade B or containing IL-6 or IL-10 were observed in the STZ group but not in the STZ+DMF group, as compared to the SHAM or SHAM+DMF groups.
2.Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2.
Schulze-Topphoff U1, Varrin-Doyer M1, Pekarek K1, Spencer CM1, Shetty A1, Sagan SA1, Cree BA2, Sobel RA3, Wipke BT4, Steinman L5, Scannevin RH4, Zamvil SS6. Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):4777-82. doi: 10.1073/pnas.1603907113. Epub 2016 Apr 13.
Dimethyl fumarate (DMF) (BG-12, Tecfidera) is a fumaric acid ester (FAE) that was advanced as a multiple sclerosis (MS) therapy largely for potential neuroprotection as it was recognized that FAEs are capable of activating the antioxidative transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway. However, DMF treatment in randomized controlled MS trials was associated with marked reductions in relapse rate and development of active brain MRI lesions, measures considered to reflect CNS inflammation. Here, we investigated the antiinflammatory contribution of Nrf2 in DMF treatment of the MS model, experimental autoimmune encephalomyelitis (EAE). C57BL/6 wild-type (WT) and Nrf2-deficient (Nrf2(-/-)) mice were immunized with myelin oligodendrocyte glycoprotein (MOG) peptide 35-55 (p35-55) for EAE induction and treated with oral DMF or vehicle daily. DMF protected WT and Nrf2(-/-) mice equally well from development of clinical and histologic EAE.
3.Dimethyl fumarate attenuates experimental autoimmune neuritis through the nuclear factor erythroid-derived 2-related factor 2/hemoxygenase-1 pathway by altering the balance of M1/M2 macrophages.
Han R1, Xiao J1, Zhai H1, Hao J2. J Neuroinflammation. 2016 May 3;13(1):97. doi: 10.1186/s12974-016-0559-x.
BACKGROUND: Guillain-Barré syndrome (GBS) is an acute, post-infectious, immune-mediated, demyelinating disease of peripheral nerves and nerve roots. Dimethyl fumarate (DMF), a fumaric acid ester, exhibits various biological activities, including multiple immunomodulatory and neuroprotective effects. However, the potential mechanism underlying the effect of DMF in GBS animal model experimental autoimmune neuritis (EAN) is unclear.
4.The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada.
Su W1, Kansal A1, Vicente C2, Deniz B3, Sarda S3. J Med Econ. 2016 Apr 15:1-10. [Epub ahead of print]
BACKGROUND: Multiple sclerosis (MS) causes significant disability and diminished quality-of-life. Delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) is a new oral treatment for relapsing-remitting MS (RRMS) approved in the US, Australia, Canada, and Europe.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related KEAP1-Nrf2 Products

CAS 846557-71-9 ML385

(CAS: 846557-71-9)

ML385 is a novel and specific inhibitor of nuclear factor erythroid 2-related factor 2 (Nrf2; IC50 = 1.9 µM), and blocks NRF2 transcriptional activity, and enha...

CAS 218600-53-4 Bardoxolone methyl

Bardoxolone methyl
(CAS: 218600-53-4)

Bardoxolone methyl (also known as “RTA 402” and “CDDO-methyl ester”) is an orally-available first-in-class synthetic triterpenoid belonging to the antioxidant i...

CAS 218600-44-3 Bardoxolone

(CAS: 218600-44-3)

Bardoxolone is a synthetic oleanane triterpenoid that exerts multifunctional activities in the control of cellular growth and differentiation. Bardoxolone is ca...

CAS 1474034-05-3 RTA-408

(CAS: 1474034-05-3)

RTA-408 is a member of the synthetic oleanane triterpenoid class of compounds and an activator of nuclear factor erythroid 2 [NF-E2]-related factor 2 (Nrf2, Nfe...

CAS 458-37-7 Curcumin

(CAS: 458-37-7)

Curcumin is the principal curcuminoid of the popular Indian spice turmeric, which is a member of the ginger family (Zingiberaceae).

CAS 624-49-7 Dimethyl Fumarate

Dimethyl Fumarate
(CAS: 624-49-7)

Dimethyl fumarate is an anti-inflammatory, a promising novel oral therapeutic option shown to reduce disease activity and progression in patients with relapsing...

CAS 932730-51-3 CDDO-EA

(CAS: 932730-51-3)

CDDO-EA is an activator of Nrf2/ARE. It has neuroprotective effect.

Chemical Structure

CAS 624-49-7 Dimethyl Fumarate

Quick Inquiry

Verification code

Featured Items